Basel, Switzerland-based TECregen has raised CHF 10 million (approximately €10.7 million / $12.6 million) in seed financing to advance a new class of thymus-rejuvenating biologics aimed at restoring immune function by rejuvenating thymic epithelial cells (TECs). The round was led by the Boehringer Ingelheim Venture Fund (BIVF) and included participation from LifeSpan Vision Ventures, Carma Fund, EOS BioInnovation, High-Tech Gründerfonds (HTGF), the JFG Life Sciences Foundation of the University of Basel, and Zurich Cantonal Bank.
The company said the financing will accelerate development of its “thymopoietic” biologics program, which targets the thymus—an organ central to the production and maturation of immune cells—and is intended to strengthen immune resilience across life stages. TECregen also positioned its approach as enabling future therapeutic opportunities spanning immunology, oncology and rare diseases, as it works toward clinical development.
Alongside the financing, TECregen appointed Dr. Bo Rode Hansen, Ph.D., MBA, as Chairman of the Board. Hansen is a longtime biotech and pharma executive who previously served as CEO of Scandion Oncology and as founding President of Genevant Sciences, and has held senior roles at Roche and Santaris Pharma. In the role, he is expected to help guide strategy and support the advancement of TECregen’s thymus rejuvenation programs.
KEY QUOTES:
“I am honored to join TECregen’s Board at such a pivotal time for the company. The team’s pioneering work in thymus regeneration has the potential to redefine treatment approaches for immune ageing and related disease. I look forward to working with the management team and our investors to accelerate the development and delivery of these transformative therapies to patients who need them most.”
Dr. Bo Rode Hansen, Ph.D., MBA, Chairman, TECregen
“We welcome Bo as our new Chairman. His wealth of industry expertise and proven leadership will be invaluable as we pursue our mission. Backed with the strong investor support, TECregen is well positioned to accelerate its thymus regeneration initiative and deliver innovative immune rejuvenation therapies to patients.”
Filippo Oliveri, Co-Founder and Board Director, TECregen
“TECregen’s innovative approach to thymus regeneration firmly positions the company at the forefront of targeted biologics designed to restore immune function, with a clear trajectory toward the clinic. The ability to modulate and restore thymic function paves the way for new therapeutic opportunities across immunology, oncology, and rare diseases. We are enthusiastic to support TECregen as it advances toward clinical development.”
Dr. Philipp Müller, Investment Manager, Boehringer Ingelheim Venture Fund (BIVF)
